Product Disease/Target Preclinical IND Phase 1 Phase 2 Phase 3 BLA
ANGEL001 Anti-PD-1 (Solid tumors)
ANGEL002 Anti-CD20 (Multiple Sclerosis)
ANGEL003 Anti-CD20/CD3
ANGEL004 Anti-VEGFR2 (Biosimilar)
ANGEL005 Anti-LAG3
ANGEL006 IL-6 (Biosimilar/Actemra)
ANGEL007 Anti-RANKL (Biobetter/Prolia)
ANGEL008 Anti-TIGIT (Solid tumors)
ANGEL009 Anti-TIM3
ANGEL010 Anti-CSF1R
ANGEL011 OX40 (agonist)
Cell Therapy
CAR-T Hematology/Oncology
TCR Hematology/Oncology
Product Disease/Target Preclinical IND Phase 1 Phase 2 Phase 3 BLA
ANGEL001 Anti-PD-1 (Solid tumors)
ANGEL002 Anti-CD20 (Multiple Sclerosis)
ANGEL003 Anti-CD20/CD3
ANGEL004 Anti-VEGFR2 (Biosimilar)
ANGEL005 Anti-LAG3
ANGEL006 IL-6 (Biosimilar/Actemra)
ANGEL007 Anti-RANKL (Biobetter/Prolia)
ANGEL008 Anti-TIGIT (Solid tumors)
ANGEL009 Anti-TIM3
ANGEL010 Anti-CSF1R
ANGEL011 OX40 (agonist)
Cell Therapy
CAR-T Hematology/Oncology
TCR Hematology/Oncology